Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.24 USD | 0.00% | -3.00% | -31.82% |
May. 09 | DA Davidson Adjusts Nu Skin Enterprises' Price Target to $12.50 From $15.50, Keeps Neutral Rating | MT |
May. 08 | Transcript : Nu Skin Enterprises, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The stock, which is currently worth 2024 to 0.48 times its sales, is clearly overvalued in comparison with peers.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.82% | 658M | C+ | ||
+12.82% | 390B | C- | ||
+17.05% | 76.55B | A+ | ||
-11.02% | 67.04B | A- | ||
-13.81% | 45.2B | B+ | ||
-10.13% | 37.05B | - | ||
+7.74% | 35.52B | B- | ||
+9.28% | 18.02B | A- | ||
+15.84% | 16.14B | B | ||
+0.16% | 11.91B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NUS Stock
- Ratings Nu Skin Enterprises, Inc.